Johnson & Johnson (NYSE: JNJ) has recently announced encouraging outcomes from the second interim analysis of the Phase 3 CARTITUDE-4 study, which is pivotal in the evolving landscape of multiple myeloma treatment. This significant study assesses the effectiveness of CARVYKTI (ciltacabtagene autoleucel; cilta-cel) against the standard therapies, which include combinations of pomalidomide, bortezomib, and dexamethasone […]
Johnson & Johnson (NYSE: JNJ), a global leader in healthcare, announced significant progress in the treatment of Sjögren’s disease (SjD) with its drug, nipocalimab. In a recent Phase 2 DAHLIAS study, patients treated with nipocalimab exhibited a statistically significant improvement in their ClinESSDAI score compared to placebo at 24 weeks (P=0.002), marking a major advancement […]
In a significant move to enhance its immunology offerings, Johnson & Johnson (NYSE: JNJ) has announced a definitive agreement to acquire a wholly-owned subsidiary of Numab Therapeutics, gaining global rights to an investigational bispecific antibody, NM26. The deal, valued at approximately $1.25 billion, is poised to transform treatment paradigms in atopic dermatitis (AD) and potentially […]
Johnson & Johnson (NYSE: JNJ) has entered into a definitive agreement to acquire Proteologix, Inc., a leading biotechnology company specializing in the development of bispecific antibodies for immune-mediated diseases. The deal, valued at $850 million in cash, also includes potential additional milestone payments. This acquisition marks a significant expansion of Johnson & Johnson’s immunology portfolio, […]
In a landmark decision, the Circuit Court of Cook County in Chicago has found Johnson & Johnson (NYSE: JNJ) and two of its subsidiaries, Johnson & Johnson Holdco, Inc., and Kenvue, Inc. (NYSE: KVUE), liable for the asbestos-related death of Theresa Garcia, a mother and grandmother. The family was awarded $45 million in damages, concluding […]
In a monumental move within the medical technology sector, Johnson & Johnson (NYSE: JNJ) has announced its acquisition of Shockwave Medical, Inc. (Nasdaq: SWAV) for a staggering $335.00 per share in cash. This acquisition, translating to an enterprise value of approximately $13.1 billion, marks a significant expansion of Johnson & Johnson’s MedTech division, specifically within […]
NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX), a leader in the field of biotechnology, announced a significant achievement in its ongoing pivotal Phase 3 study, NANORAY-312. The study, which is evaluating the potential first-in-class radioenhancer NBTXR3 for elderly patients with head and neck cancer, has met operational requirements, resulting in a $20 million milestone payment from […]
Bausch + Lomb, an esteemed global eye health company, has broadened its portfolio by purchasing Johnson & Johnson Vision’s Blink product line for $106.5 million. The acquisition, financed using existing cash, underscores Bausch + Lomb’s ongoing commitment to enhancing consumer convenience in over-the-counter (OTC) eye care. The Blink range, now under Bausch + Lomb’s umbrella, […]
Marksans Pharma said that it has been granted final approval for the over-the-counter (OTC) use of Famotidine Tablets USP, 10 mg and 20 mg from the US Food and Drugs Administration (FDA). Famotidine Tablets is bioequivalent to Pepcid AC tablets, said the India-based pharma company. The reference listed drug (RLD) is owned by Johnson & […]
Johnson & Johnson (J&J) has closed the previously announced acquisition of Abiomed, a medical device technology company, for an enterprise value of around $16.6bn, in a move to strengthen its MedTech portfolio. The acquisition of Abiomed, which was announced in November 2022, is expected to add heart recovery solutions to the MedTech portfolio of Johnson […]
